ZENSUN ENT Reports Interim Loss Narrowed by 40% to Around RMB 301 Million
Stock News
Aug 31
ZENSUN ENT (00185) has released its interim results for the six months ended June 30, 2026, revealing a substantial narrowing of its net loss year-on-year.
The group recorded revenue of approximately RMB 357 million for the period, marking a steep decline of about 86.4% compared to the same period last year.
Despite the sharp drop in top-line performance, the company's loss attributable to shareholders came in at roughly RMB 301 million, a reduction of approximately 40.0% from the prior corresponding period.
Basic loss per share stood at RMB 15.7 cents, reflecting the improved bottom-line figure against the backdrop of reduced operational scale.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.